Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) soared after making an announcement on Friday when markets were gone closed that the company successfully achieved FDA approval for Korlym. The drug is a once-daily experimental medicine which is used for the treatment of hyperglycemia secondary to hypercortisolism in adult patients suffering from endogenous Cushing’s syndrome who have diabetes mellitus type 2 or glucose intolerance and have failed surgery or are not candidates for surgery.

The stock topped eight-month high price during the trade and finally gained 46.86% to $4.45 with surprised volume of 11.89 million shares. Rating agency JMP Securities repeated its earlier rating of Mkt Outperform for the stock but improved its price target price from $9 to $11.

While taking into consideration more best stocks in biotechnology group holding volume of more than 1 million shares Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) followed CORT with rally of more than 40% while Galena Biopharma Inc (NASDAQ:GALE) gained 9.71%, Cell Therapeutics, Inc. (NASDAQ:CTIC) advanced 5.19% and Complete Genomics, Inc. (NASDAQ:GNOM) moved up 2.81%.

Threshold Pharmaceuticals, Inc. kicked off the last session at an opening price of $5.87 and gained as much as to reach $6.65 but later by the trade end stock surged 1.93% to $5.01.

On the other hand, its trade volume of 28.03 million shares was higher than average trading capacity of 1.98 million shares. The company’s week performance emerged as +63.73%, 1 year performance moved at +114.10%, and year-to-date performance appeared positive with +310.66% while a month-performance after last trade close went up at +227.45%.

The stock price volatility was 17.34% for a week and 13.06% for a month as well as price volatility’s Average True Range for 14 days was 0.53 and its beta remained 1.34.

THLD earned -$26.93 million. The liquidity measure in recent quarter results of the company was recorded +4.85 as current ratio. THLD had a cash of $0.51 per share and a book value per share as $0.19 in the most recent quarter.

On the flip side, GTx, Inc. (NASDAQ:GTXI) led losers as plunged 36.38% after FDA put a hold on its clinical trials evaluating Capesaris but edged up in extended trading as is going to release quarterly results today. In addition, Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) fell 12.19%, Codexis, Inc. (NASDAQ:CDXS) dropped 19.21%, VIVUS, Inc. (NASDAQ:VVUS) slumped 12.01% and BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) slipped 9.37%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. galaxystocks.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer ( http://galaxystocks.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold galaxystocks.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.